Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02127710 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
A Phase 2 study of Papillary Renal Cell Cancer, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
- 20
- Study locations
NCT02127710: Completed Phase 2 study of Papillary Renal Cell Cancer, sponsored by AstraZeneca.
NCT02127710 is a Phase 2 study of Papillary Renal Cell Cancer that has completed, run by AstraZeneca. The registered enrollment target is 111 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02127710, a Phase 2 study of Papillary Renal Cell Cancer, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated. An independent central pathology review of tumour samples will be used to confirm the diagnosis of PRCC of all patients enrolling. However, locally available pathology results confirming PRCC will be allowed for timely study entry.
Primary Outcome
The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to Response Evaluation Criteria for Solid Tumours (RECIST) v1.1.
Conditions Studied
Interventions
- DRUG AZD6094
Study Locations (20)
Other
- Research Site - Barcelona
- Research Site - Cambridge
- Research Site - Glasgow
California
- Research Site - Duarte
- Research Site - Palo Alto
Texas
- Research Site - Dallas
- Research Site - Houston
Alberta
- Research Site - Calgary
- Research Site - Edmonton
Ontario
- Research Site - Toronto
- Research Site - Toronto
Alabama
- Research Site - Birmingham
Florida
- Research Site - Fort Myers
Illinois
- Research Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-04-30 |
| Est. Completion | 2020-04-20 |
| Phase | Phase 2 |
What the finished NCT02127710 record still lists
NCT02127710 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Papillary Renal Cell Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD6094 is the first listed.
NCT02127710 names 20 study sites across 14 states, led by Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT02127710 about?
NCT02127710 is a clinical study titled "A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)". This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated. An independent central pathology review of tumour samples will be used...
What is the current status of trial NCT02127710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2014-04-30. Estimated completion is 2020-04-20.
What conditions does trial NCT02127710 study?
This clinical trial studies the following conditions: Papillary Renal Cell Cancer.
What interventions are being tested in trial NCT02127710?
The interventions under investigation include: AZD6094 (DRUG).
Who is sponsoring clinical trial NCT02127710?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02127710 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02127710's enrollment target sits among peer trials
111 632nd of 2000 higher than 1,369 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI